Cue Health’s New Suite of At-Home Diagnostic Tests and Expansion of Cue Care Puts You in Control of Your Health
March 13 2023 - 9:15AM
Business Wire
Get actionable health information and
convenient access to treatment for a wide range of general health
& wellness conditions, including sexual, heart, and metabolic
health
Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology
company, today announced the nationwide launch of a new suite of
consumer-friendly, at-home diagnostic test kits. These easy-to-use
kits provide individuals with access to accurate, reliable testing
from the comfort of their own homes, making it easier for people to
take control of their health. The tests are integrated into Cue
Care – the company’s innovative test-to-treat service. Cue provides
personalized care and access to convenient treatment, including
e-prescriptions and medication delivery, from the privacy of
home.
Each Cue Health at-home test kit includes all of the supplies
needed for safe, easy, and private sample collection. After the
sample is sent to and processed by an independent, CLIA-certified
laboratory, easy-to-understand results are securely delivered back
to the customer in the Cue Health App, along with information about
their condition or concern. Customers can then choose to use Cue
Care to consult virtually with a healthcare provider and receive
personalized care and, if appropriate, treatment delivered
quickly.
The following Cue Health test kits are now available, with more
planned over time:
Heart Health Test Kits
- Heart Health Panel
- Cardiac Risk Apo A+B Test
Sexual Health Test Kits
- Chlamydia and Gonorrhea
- Herpes Panel
- Men’s Sexual Health Panel
- Women’s Sexual Health Panel
Women’s Health Test Kits
- Women's Fertility Panel
- Women's Health Panel
Metabolic Health Test Kits
Wellness Test Kits
- Food Sensitivity Panel
- Colon Cancer Screening
- Vitamin D Test
“Our new suite of at-home diagnostic test kits puts people in
greater control of their health by providing more actionable
information about a wide variety of common conditions that often go
undiagnosed and untreated,” said Clint Sever, Chief Product Officer
of Cue Health. “These health and wellness tests complement our
diagnostic testing strategy, and we continue to make progress
developing new tests for respiratory, sexual, and metabolic health
using our innovative technology.”
“We are breaking down barriers in healthcare delivery to make
at-home testing easier to access and act upon,” added Dr. David
Tsay, Chief Medical Officer for Cue Health. “Americans are now
embracing accessing healthcare from the convenience of their home.
So we seamlessly integrated these new test kits into our platform,
empowering people to consult with a provider immediately after they
get their test result so they can make timely and informed
decisions about their health. We are committed to improving public
health outcomes, and believe that these innovations will help us
achieve that goal.”
This new suite of at-home diagnostic tests is available for
purchase in the Cue Health App and on the Cue Health website. In
the near future, Cue will look to further expand Cue Care and
address even more common conditions and health concerns.
For press assets, please visit here.
About Cue Health
Cue Health (Nasdaq: HLTH) is a healthcare technology company
that makes it easier for individuals to access health information
and places diagnostic information at the center of care. Cue Health
enables people to manage their health through real-time,
actionable, and connected health information, offering individuals
and their healthcare providers easy access to lab-quality
diagnostics anywhere, anytime, in a device that fits in the palm of
the hand. Cue Health's first-of-its-kind COVID-19 test was the
first FDA-authorized molecular diagnostic test for at-home and
over-the-counter use without a prescription and physician
supervision. Outside the United States, Cue Health has received the
CE mark in the European Union, Interim Order authorization from
Health Canada, regulatory approval from India's Central Drugs
Standard Control Organization, and PSAR authorization from
Singapore’s Health Sciences Authority. Cue was founded in 2010 and
is headquartered in San Diego. For more information, please visit
www.cuehealth.com.
Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
“forward-looking statements”. The words, without limitation,
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these or similar identifying
words. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including those related to the expected future diagnostic
test menu and the factors discussed in the “Risk Factors” section
of Cue’s Annual Report on Form 10-K for the year ended December 31,
2021 and Quarterly Report on Form 10-Q for the quarter ended
September 30, 2022 filed with the SEC on November 9, 2022. Any
forward-looking statements contained in this press release are
based on the current expectations of Cue’s management team and
speak only as of the date hereof, and Cue specifically disclaims
any obligation to update any forward-looking statement, whether as
a result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230313005300/en/
MEDIA INQUIRIES press@cuehealth.com
Cue Health (NASDAQ:HLTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cue Health (NASDAQ:HLTH)
Historical Stock Chart
From Jul 2023 to Jul 2024